{Reference Type}: Case Reports
{Title}: Carcinoma of the salivary glands: guidelines and case report of sustained remission with docetaxel.
{Author}: Arrondeau J;Le Nagat S;Lefèvre M;Tassart M;Touboul E;Lacau St Guily J;Huguet F;
{Journal}: J Clin Pharm Ther
{Volume}: 40
{Issue}: 1
{Year}: Feb 2015
{Factor}: 2.145
{DOI}: 10.1111/jcpt.12221
{Abstract}: <B>OBJECTIVE: </B>Salivary glands tumours are rare neoplasms for which there are few clinical trials. The most common malignant parotid tumour is the mucoepidermoid carcinoma. High-grade mucoepidermoid carcinomas are highly aggressive tumours. The initial therapy of localized disease is known, but when there is a recurrence, several options are possible and chemotherapy is generally reserved for palliative treatment. We comment on published guidelines and report a case of sustained remission with docetaxel.<BR><B>METHODS: </B>Our case concerns a 64-year-old woman with a high-grade mucoepidermoid carcinoma of the parotid gland with local recurrence treated with docetaxel 50 mg/m² every 15 days. After the sixth cycle, a complete remission was observed on CT-scan. The tolerability was excellent. After 2 years of docetaxel, the patient was still in complete remission.<BR><B>CONCLUSIONS: </B>Docetaxel is an active drug for the treatment of mucoepidermoid carcinoma of salivary glands. A prospective study should confirm these data.